Latest News

According to the company, this meeting helped to provide a “clear path forward” for CBT-004 in its projected phase 3 study

This enables the initiation of the EYETAC phase II clinical trial (NCT07285070) in patients with non-infectious anterior uveitis (NIAU).

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

A study reveals that low-dose pilocarpine effectively reduces pupil size in presbyopic eyes with minimal impact on lens thickness and accommodation.

This one-day symposium on January 31, 2026, will bring together clinicians and experts at the University Eye Clinic in Mainz to discuss optic neuropathies and diagnostic trends.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

FDA authorizes compassionate use of urcosimod for neuropathic corneal pain, a condition that causes severe pain and sensitivity of the eyes, face, or head.

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).